If you are retail in this stock you are just along for the ride. Every non revenue biotech must dilute to stay afloat. Most dilute all equally. GALT will dilute mostly those that can not subscribe to the new stock subscription program. The Chairman will buy 20 million in stock and warrants with a 5 strike. Only current investors that are also certified accredited investors may do the same. Other current shareholders will be diluted. Also puts a resistance level in above $5 as warrants can be exercised at that price. Positives are much needed cash is coming and the stock is going into strong hands and it is less dilution than another type of cash raise. Also makes a takeover buy new entity more expensive. Negatives it dilutes the common shareholders who can not subscribe to the stock/warrants purchase plan nor can new investors who might be dissuaded by entering at this time just to be immediately diluted. This stock may continue to correct downward as a result of this in the short term but in the long term will be favorable as the Company will now have cash to move forward with the very promising clinical trials. Looks like the sell the Company before the end of 2018 was not fruitful. Maybe because potential suitors were playing hardball because Gallactin was cash strapped. I urge everyone to read Uihien's March 6 open letter to shareholders. Long term good news with some temporary pain to common stock holders. I might look to enter in a quarter or two when the warrants do not present as much of a cap on the share price and trials are underway in earnest.
News 
Market Data 
Discover 
AI
